Bone Biologics (BBLGW) Common Equity (2010 - 2026)

Bone Biologics (BBLGW) has reported Common Equity for 17 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 40.5% year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $3.9 million, a 40.5% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, up 54.37% from the prior year.
• Common Equity was $3.9 million for Q2 2026 at Bone Biologics, down from $5.4 million in the prior quarter.
• Over five years, Common Equity peaked at $6.6 million in Q2 2025 and troughed at $2.8 million in Q1 2023.
• A 5-year average of $4.5 million and a median of $3.9 million in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 142.76% in 2022 and plunged 54.09% in 2023, its largest moves.
• Over 5 years, Common Equity stood at $5.9 million in 2022, then plunged by 51.13% to $2.9 million in 2023, then climbed by 19.86% to $3.5 million in 2024, then soared by 54.37% to $5.4 million in 2025, then dropped by 27.02% to $3.9 million in 2026.
• The last three Common Equity figures came in at $3.9 million (Q2 2026), $5.4 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.